DOCSLIB.ORG

Immunotherapy for Cancer Kara L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunotherapy for Cancer� Kara L Immunotherapy for Cancer! Kara L. Davis, D.O.! Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases! Assistant Professor of Pediatrics! Bass Center for Childhood Cancer and Blood Disorders! Stanford University! ! Objectives! • Childhood leukemia leads the way for targeted T- cell therapies! • What are chimeric antigen T cells! • Use in heme malignancies and solid tumors! • Limitations in Efficacy! • Toxicity concerns! • Immune Checkpoint Inhibition for anti-cancer effect! • Successes and Challenges! Childhood Leukemia was universally fatal 100 years ago! Gittins, Arch. Dis Child, 1933! Now childhood leukemia is a poster child for success in cancer treatment! Pui et al, NEJM 2006! Survival after relapse from childhood ALL K Nguyen et al 2147 Table 4 Univariate analyses of risk factors associated with survival after relapse Univariate analyses of survival post 5-year survival rates P-value relapse risk factors (N 1961) post relapse±s.e. (%) ¼ Time to relapse Early 21.0±1.8 o0.0001 Intermediate 37.9±2.7 Late 53.1±3.9 Relapse site Isolated marrow 24.1±2.1 o0.0001 Concurrent marrow 39.4±5.0 Isolated CNS 58.7±3.2 Isolated testicular 58.0±8.2 Other extramed±CNS 55.9±9.9 Figure 2 Kaplan–Meier estimates of survival after relapse for patients Age group stratified by NCI risk group at diagnosis and timing of relapse. There o1 year 19.8±4.4 o0.0001 were significant differences in outcome for those SR vs HR patients 1–9 years 45.0±2.1 experiencing either an early (33.1±3.6 vs 14.9±2.1%, Po0.0001), 10+ years 18.2±2.8 intermediate (52.2±3.7 vs 22.0±3.9%, Po0.0001) or late relapse (59.6±4.6 vs 39.5±7.2%, Po0.0001). Trial era But relapsed leukemia is still a bigEarly problem! 36.2±1.9 0.66 Late 36.6±3.1 Sex Male 35.4±2.2 0.51 • OverFemale time, from 38.0±2.5 Lineage 1988-2002B studies 37.2±2.1 o0.0001 addressingT relapsed23.0 ±ALL4.0 CNS status at diagnosis haveCNS-3 not improved 14.5±4.5 o0.0001 CNS-2 and CNS-1 37.7±1.7 outcomes ! WBC o50 k 41.6±2.0 o0.0001 X50 k 24.3±2.6 Race White 38.5±2.0 0.02 Hispanic 30.5±3.8 Figure 3 Kaplan–Meier estimates of survival after relapse for patients Black 30.1±5.9 stratified by treatment era and timing of relapse. There was no Other Nguyen et al, Leukemia,38.1±6.9 2008! difference in survival between early and late trials among patients who ± ± experienced an early relapse (19.3 2.1 vs 23.4 3.4%, P 0.10), or NCI risk intermediate relapse (39.3±3.3 vs 36.0±4.8%, P 0.49)¼ or late Standard 50.4±2.4 o0.0001 relapses (53.3±4.3 vs 54.4±9.2%, P 0.66). ¼ ¼ High 22.6±2.1 CCG-1952, CCG-1953, CCG-1961 and CCG-1962. A total of Abbreviations: CNS, central nervous system; NCI, National Cancer 1961 children were included in this analysis (Figure 3). The Institute; WBC, white blood cells. results demonstrated that patients who relapsed early had dismal survival regardless of treatment era (5-year post-relapse survival: 19.3±2.1 vs 23.4±3.4%, P 0.10). Similarly, there were no diagnosis were excluded from the multivariate analyses, as they ¼ statistically significant differences in survival between those cannot be classified by NCI risk group. Age at diagnosis, CNS treated on early and late trials, for patients experiencing either disease, sex, lineage and NCI risk group were significant an intermediate (39.3±3.3 vs 36.0±4.8%, P 0.49) or late predictors of survival post relapse. Trial era, WBC at diagnosis ¼ relapse (53.3±4.3 vs 54.4±9.2%, P 0.66). and race were not significant in predicting survival in the ¼ Univariate analyses (n 1961) were conducted to study the multivariate analysis. Multivariate analyses stratified for time ¼ association of presenting clinical and laboratory features at to relapse, the site of relapse and age at diagnosis resulted in initial diagnosis, time to relapse and the site of relapse with the same significant predictors as before. Trial era, WBC at survival post relapse (Table 4). Significant associations were diagnosis and race were not significant factors. found with site and timing of relapse, age at diagnosis, WBC at diagnosis, lineage (B vs T), CNS status at diagnosis, race and NCI risk; exceptions were trial era and sex. Multivariate analyses Discussion stratified by timing of relapse and the site of relapse were conducted on the subset of patients (n 1391) with complete Despite improved treatments and increasing dose intensity in ¼ data for all the variables (Table 5). Infants o1 year of age at primary therapy for newly diagnosed patients with ALL, patients Leukemia The search for surface targets in B cell cancers! Piccaluga et al., Leuk & Lymphoma 2010! What is a CAR-T cell?! ! VH! V V VL scFv! L! H! α β ε δ ϒ ε + TM! . CD28/41BB! ζ ζ costim CD3#! Monoclonal antibody! T-cell Receptor! Chimeric Antigen Receptor! How CAR-T cells work…! T cell! Tumor cell! CAR enables T cell to Expression of recognize tumor cell CAR! antigen! Viral DNA! Insertion! Antigen! Tumor cell CAR T cells! apoptosis! multiply and release cytokines! Courtesy of David Miklos! Timeline of Development! CAR T cells: CAR design impacts function! Therapeutic Advances in Hematology 6(5) First generation CAR Second generation CAR Third generation CAR ScFv antigen-binding domain VH VH VH V V V L L L hinge linker Costim C Costim C CD3 ‘first signal’ ‘first signal’ ‘first signal’ CD28 CD137 (4-1BB) 1 1 Costim C CD3 CD27 CD28 ‘second signal’ ‘second signal’ CD134 (OX40) 2 CD137 (4-1BB) CD3 ‘third signal’ Tasian et al., Ther Adv Hema, 2015! Figure 1. Generations of chimeric antigen receptors (CARs) utilized in clinical testing. Constructs encoding synthetic CARs targeting tumor-associated antigens (such as CD19) can be stably transduced into human T cells for infusion into patients with relapsed/refractory cancer. CARs are comprised of (1) an extracellular MHC- independent antigen-binding domain usually derived from a monoclonal antibody single chain variable fragment (ScFv), (2) an extracellular spacer domain or ‘hinge’ (in some CARs), (3) a transmembrane linking domain and (4) an intracellular co-stimulatory T cell signaling domain or multiple domains. With increased understanding of the critical Given the potential for clinically significant CAR importance of the intracellular ‘second signal’ T-cell induced toxicities (discussed below), opti - activation for CAR T-cell efficacy, subsequent mal CAR design thus must carefully balance generations of CARs have optimized ScFv and desired antitumor potency with minimization of linker component design and, more importantly, hazardous side effects [Gardner and Jensen, 2014]. have incorporated additional intracellular costim- ulatory signaling domains [e.g. CD27, CD28, Various groups have focused intensively in the past CD134 (OX40), CD137 (4-1BB)] in efforts to decade on targeting the B-lymphocyte antigen, increase the expansion, persistence and potency CD19, a phosphoglycoprotein ubiquitously of CAR T cells, as well as to prevent cellular expressed on malignant and nonmalignant B-cells. exhaustion in vivo (Figure 2). Based upon the clinical efficacy and apparent toler- ability of targeting CD20 (another commonly Most CARs used in current clinical trials of engi- expressed B cell antigen) with the anti-CD20 mon- neered T cells for patients with B-ALL are derived oclonal antibody rituximab in patients with B-cell from second generation constructs with CD3ζ hematologic malignancies [Cramer and Hallek, and another signaling endodomain. Delivery of a 2012], it was hypothesized that the CD19 receptor second costimulatory signal has indeed appeared could be similarly targeted with engineered T cells to induce significantly greater T-cell expansion expressing a CD19-redirected CAR and that treat- and longer-term persistence in vivo to date in ment with these CD19 CAR T cells would also be treated patients. ultimately tolerable in patients [Cooper et al. 2004; Kochenderfer and Rosenberg, 2013]. Third generation CAR constructs comprised of CD3ζ and two additional co-stimulatory endodo- In preclinical studies, several research teams mains transduced into T cells are also under clini- observed that co-incubation of CD19 CAR T cells cal evaluation, but have not thus far resulted in with B-cell leukemia or lymphoma cell lines greater efficacy than second generation CARs induced potent T-cell degranulation, cytokine [Davila et al. 2012; Sadelain et al. 2013; Kenderian production and tumor cytotoxicity in vitro. et al. 2014; Mackall et al. 2014]. Furthermore, treatment of human ALL cell 230 http://tah.sagepub.com Design affects Function! CD19-CD28-Zeta CD19-41BB-Zeta V V H Anti-CD19 H Anti-CD19 VL VL NCI! TM vs. TM UPENN! KITE! NOVARTIS! MSKCC! CD28 4-1BB! SEATTLE! JUNO (JCAR015)! JUNO (JCAR017)! CD3ζ CD3ζ Persist less than 3 months Persist 6 months or more in most patients in most patients Increased Persistence of CD19.BB.z vs CD19.28.z CAR in Clinical TrialsCD19-CAR! 100000 CD19.28.z-Bethesda CD19.BB.z-Penn 10000 1000 100 10 1 0 3 6 9 12 Days Since Infusion 0.1 transgene copies/100 ng of DNA 0 7 14 21 28 35 42 49 56 100 200 300 Lee, Lancet, 2014! Days Since Infusion Months Since Infusion Maude, NEJM, 2014! Efficacy of CAR-T cells ! Current strategies for treatment after relapse are suboptimal! Clo/CTX/VP-16 for Advanced Childhood ALL Clofarabine, Etoposide, CyclophosphamideBlinatumomab! ! Locatelli et al, Br J Haematol, 2009! Fig 3.
Load more

Recommended publications
  • 7Th Annual Center for Human Immunology Symposium
    7th Annual CHIS Center for Human Immunology Symposium September 26, 2013 BloodCenter and Blood Research Institute: Discoveries, Diagnosis and Treatment A Brief History BloodCenter of Wisconsin (BCW) is a private, not-for-profit organization that provides blood, blood products, and specialized transfusion medicine services to hospitals in Wisconsin. In partnering with Heartland Blood Centers, BCW also serves northern Illinois and parts of Indiana. A commitment to pursue research and advance the understanding of blood and blood transfusions was written into the articles of incorporation by visionary members of the board of directors when BCW was founded in 1947. The current mission statement calls for BCW to “advance patient care by providing life-saving solutions grounded in unparalleled medical and scientific expertise.” The Junior League of Milwaukee founded the Junior League Blood Center in 1947 as a community blood bank with five paid staff and 70 regular volunteers. By 1952, the center was serving 30 regional hospitals. The name was changed to Milwaukee Blood Center in 1954 and an active research focus was initiated in the early 1950s. The first federal grant was received by the Milwaukee Blood Center in 1957. The name of the center was changed to the Blood Center of Southeastern Wisconsin in 1979 and again to BloodCenter of Wisconsin in 2005 to more accurately reflect the geographically growing area of its service. With the success of life-saving discoveries, increased research funding and committed scientific staff, BCW built the Blood Research Institute (BRI) on the grounds of the Milwaukee Regional Medical Center in 1991. Over the years, the contributions of BloodCenter investigators have made a lasting impact on the fields of Transfusion Medicine, Immunology and Vascular Biology.
    [Show full text]
  • Chimeric Antigen Receptors As New Targeted Therapies for Childhood Cancer
    CCR FOCUS The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer Daniel W. Lee1, David M. Barrett2,3, Crystal Mackall1, Rimas Orentas1, and Stephan A. Grupp2,3 Abstract Improved outcomes for children with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, gene therapy, and cell-processing technologies have paved the way for clinical applications of chimeric antigen receptor–based therapies. This is a new form of targeted immuno- therapy that merges the exquisite targeting specificity of monoclonal antibodies with the potent cytotoxicity, potential for expansion, and long-term persistence provided by cytotoxic T cells. Although this field is still in its infancy, clinical trials have already shown clinically significant antitumor activity in neuroblastoma, chronic lymphocytic leukemia, and B-cell lymphoma, and trials targeting a variety of other adult and pediatric malignancies are under way. Ongoing work is focused on identifying optimal tumor targets and elucidating and manipulating both cell- and host-associated factors to support expansion and persistence of the genetically engineered cells in vivo. In pediatric oncology, CD19 and GD2 are compelling antigens that have already been identified for targeting pre-B acute lymphoblastic leukemia and neuroblastoma, respectively, with this approach, but it is likely that other antigens expressed in a variety of childhood cancers will also soon be targeted using this therapy. The potential to target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be made opens up an entirely new arena for targeted therapy of childhood cancer.
    [Show full text]
  • Curriculum Vitae
    CURRICULUM VITAE Name: Crystal L. Mackall, M.D. Contact Information: 265 Campus Dr., G3141A, MC5456 Stanford, CA 94305 Phone: 650-725-9670 EmaIl: [email protected] Citizenship: UnitEd StatEs Education: 1980 B.S. (Natural ScIEncEs, summa cum laude), UniversIty of Akron, Akron, Ohio 1984 M.D., NortheastErn Ohio UniversItIEs CollEge of MEdicIne, Rootstown, Ohio Brief Chronology of Employment: 1984 - 1988 ResIdency, Combined PEdiatrics/IntErnal MEdicIne; Children's Hospital MEdical CentEr of Akron/Akron GEneral MEdical CentEr, Akron, Ohio 1989 – 1992 FEllowship PEdiatric HEmatology/Oncology; PEdiatric Branch, NCI, NIH, Bethesda, MD 1992-1996 InvestIgator, ExperimEntal Immunology Branch, NCI, NIH 1996-1998 InvestIgator, PEdiatric Oncology Branch, NCI, NIH 1998-2003 PrincIpal InvestIgator, TEnure Track, PEdiatric Oncology Branch, NCI, NIH 2003-2015 TEnured PrincIpal InvestIgator and HEad, Immunology SEctIon, PEdiatric Oncology Branch, NCI, NIH 2005 DEputy Branch ChiEf, PEdiatric Oncology Branch, NCI, NIH 2005-2008 ActIng Branch ChiEf, PEdiatric Oncology Branch, NCI, NIH 2008-2015 ChiEf, PEdiatric Oncology Branch, NCI, NIH 2016-2018 EndowEd Professor of PEdiatrics and MEdicIne, Stanford UniversIty 2018-presEnt Ernest and AmElIa Gallo FamIly Professor of PEdiatrics and MEdicIne, Stanford UniversIty Military Service: 1980-2010 UnitEd StatEs PublIc HEalth SErvicE, CaptaIn 0-6, retIred Hospital Appointments and Major Administrative Leadership Positions: 2016-presEnt AssocIatE DIrector, Stanford CancEr InstItutE 2016-presEnt ActIve Staff, LucIlE
    [Show full text]
  • View My Sister Says, “Maria Grazia, How Do You CLICK to READ Same Position As It Should Be
    SPRING 2017 SPRING ’ PackardThe magazine of the Lucile Packard Foundation for Children’s Children Health Newss CURING THE INCURABLE Translating discoveries into cures—faster inside: 2016 Report on Giving No Longer Conjoined, Sandoval Twins Return Home ’ Packard ChildrenNewss SPRING 2017 Volume 18, Number 1 EDITOR IN THIS ISSUE Jennifer Yuan ASSOCIATE EDITORS Megan Alpers-Raschefsky Lindsay Okamoto WEB EDITORS What childhood diseases can we Manya Khan Ali Koide cure next, with your support? WRITERS Tom Ahern Giselle Contreras and In my 35 years as a pediatrician, I’ve seen amazing improvement in the way Gabriella Medrano-Contreras Julie Greicius we take care of children. Many of the infectious diseases that caused kids to Jennifer Yuan be hospitalized during my residency are now almost medical history. Child- DESIGN 22 18 Andrea Hopkins Design hood cancer survival has jumped from 50 to over 80 percent. And today, there PHOTOGRAPHY are more surviving adults than children with congenital heart disease. Douglas Peck Norbert von der Groeben— What brought about all this change? Research. Decades of innovative and Stanford School of Medicine Elena Zhukova painstaking work by physicians and researchers, backed with the funding to LUCILE PACKARD FOUNDATION make change happen. FOR CHILDREN’S HEALTH Our work is not finished yet. When children are seriously ill, the two main BOARD OF DIRECTORS treatment options are still medication or surgery, sometimes accompanied by Elaine Chambers, Chair Manuel Henriquez, Vice Chair terrible side effects and a compromised quality of life. But through research, Mindy Rogers, Secretary C. Bryan Cameron, Treasurer new hope is emerging every day.
    [Show full text]
  • Celebrates Women Leadership in Immuno-Oncology Editor and Director’S Note
    IO360° Celebrates Women Leadership in Immuno-Oncology Editor and Director’s Note IO360° is proud to celebrate women’s leadership in Immuno-Oncology. We presented a variety of IO360° women speakers over the past 10 weeks, highlighting their incredible work in IO. We created the Q&A series to not only spotlight the work these women are leading in IO, but also to touch on the things that they are passionate about and how they are encouraging other women in STEM. The highlighted speakers represent a variety of backgrounds in life sciences including industry, government, academic and technology, both for- and non-profits. They are directors, heads of departments, chief scientists, presidents and CEOs. Their work in science pushes our knowledge of cancer further, from advancing imaging techniques to utilizing genomics and creating the next generation of cellular medicine. In this Q&A series, we learn about what inspires the speakers, what they’re excited about, what they’re working on and what advice they would pass along to other women. We are pleased and honored to present this series. Thank you to everyone who participated. Sincerely, Kate Woda Danny McCarthy Director Content Writer & Editor Immuno-Oncology 360° Immuno-Oncology 360° Crystal Mackall, MD Professor of Pediatrics and Medicine Stanford University School of Medicine On Excitement for Immunotherapy, Foraying into Solid Tumors and Her Transition to Academia In 2016, you transitioned from NCI to Stanford What inspired you to pursue medicine? University. How has the transition been? The NCI was an incredible place to grow up as a scientist, in I always knew I wanted to be a physician, and when I started particular somebody who was interested in the translational rotating on the wards, it was clear that cancer demanded the interface.
    [Show full text]
  • Expanding the Success of Immune Effector Cell Therapies for Cancer Pre-Meeting Workshop Table of Contents
    Monday, May 10 3 - 7 p.m. ET Expanding the Success of Immune Effector Cell Therapies for Cancer Pre-Meeting Workshop Table of Contents Sponsors 3 Schedule 5 Speakers 9 Disclosures 21 2 Sponsors The American Society of Gene & Cell Therapy is honored to acknowledge the following organizations for their support of Expanding the Success of Immune Effector Cell Therapies for Cancer: 3 Schedule Expanding the Success of Immune Effector Cell Therapies for Cancer Co-Chairs: Terry Fry, M.D., and Sarah Nikiforow, M.D., Ph.D. 3 - 3:23 p.m. Rational Synthetic Receptor Design: Signaling Gianpietro Dotti, M.D., UNC Lineberger Cancer Center 3:23 - 3:46 p.m. Engineering CAR T Cells to Overcome Therapeutic Resistance Robbie Majzner, M.D., Stanford University School of Medicine 3:46 - 4:09 p.m. Challenges of Simultaneous Targeting CD19 and CD22 - Insights from Design and Clinical Experimental Martin Pule, M.D., University College London 4:09 - 4:19 p.m. Panel Discussion Gianpietro Dotti, M.D., UNC Lineberger Cancer Center Robbie Majzner, M.D., Stanford University School of Medicine Martin Pule, M.D., University College London 4:19- 4:42 p.m. Challenges of Immune Effector Cell Therapies: Genomics and Transcriptomics of Leukemic Relapse Andrei Thomas-Tikhonenko, Ph.D., Children's Hospital of Philadelphia 5 Schedule Expanding the Success of Immune Effector Cell Therapies for Cancer 4:42 - 5:05 p.m. Challenges of Immune Effector Cell Therapies: Toxicity Bianca Santomasso, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center 5:05 - 5:28 p.m. Challenges in Adoptive Cell Therapies: Manufacturing & Access Isabelle Rivière, Ph.D., Memorial Sloan-Kettering Cancer Center 5:28 - 5:38 p.m.
    [Show full text]
  • CAR T-Cell Therapy Horizon Scanning
    CAR T-Cell Therapy Horizon Scanning EBEU Report No. 11/2020 AIHTA Policy Brief No. 006a CAR T-Cell Therapy Horizon Scanning EBEU Report No. 11/2020 AIHTA Policy Brief No. 006a Innsbruck, August 2020 Project Team Project leader: Dr. MMag. Sabine Geiger-Gritsch, Evidenzbasierte Entscheidungsunterstützung (EBEU) - Medizinisches Projektmanagement, Tirol Kliniken GmbH, Innsbruck Project support: Univ.-Prof. Dr. Christian J. Wiedermann, Medizinischer Geschäftsführer, Tirol Kliniken GmbH, Innsbruck External Review: PD Dr. Claudia Wild, HTA Austria - Austrian Institute for Health Technology Assessment GmbH, Vienna Correspondence: Sabine Geiger-Gritsch, [email protected] Conflict of Interest All authors declared they have no conflicts of interest according to the Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org). This report should be referenced as follows: Geiger-Gritsch S, Wiedermann C. CAR T-Cell Therapy, Horizon Scanning. EBEU Report No. 11/2020; AIHTA Policy Brief No. 6a/2020, Innsbruck/Vienna. Tirol Kliniken GmbH Innsbruck in Collaboration with the Austrian Institute for Health Technology Assessment GmbH Die AIHTA Policy Briefs erscheinen unregelmässig und dienen der Veröffentlichung der Forschungsergebnisse des Austrian Institute for Health Technology Assessment. Die AIHTA Policy Briefs erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver "https://eprints.aihta.at/view/types/policy=5Fbrief.html" der Öffentlichkeit zur Verfügung gestellt AIHTA Policy Brief
    [Show full text]
  • Phase I and Phase II Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation
    Phase I and Phase II Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries Christina Baggott, RN, PhD [email protected] AML, ALL Catherine Aftandilian, MD, MS [email protected] Norman Lacayo, MD [email protected] Gary Dahl, MD [email protected] Bone and Soft Tissue Sarcomas, Sheri Spunt, MD, MBA [email protected] Renal Tumors HLH Michael Jeng, MD [email protected] Hodgkin’s Lymphoma Michael Link, MD [email protected] Immunotherapy Crystal Mackall, MD [email protected] Kara Davis, DO [email protected] Liver Tumors, Germ Cell Tumors Arun Rangaswami, MD [email protected] Neuroblastoma Robbie Majzner, MD [email protected] Neuro-Oncology Sonia Partap, MD [email protected] Paul Fisher, MD [email protected] Cynthia Campen, MD [email protected] Michelle Monje, MD [email protected] Non-Hodgkin’s Lymphoma Sandra Luna-Fineman, MD [email protected] Stem Cell Transplantation Maria Grazia Roncarolo, MD [email protected] Rajni Agarwal-Hashmi, MD [email protected] Oncology: Leukemia/Lymphoma NCT #/Phase Title Sponsor Investigator Contact Phase I TINI: Total Therapy for Infants with Acute Lymphoblastic St. Jude Norman Christina (NCT02553460) Leukemia (ALL) Lacayo Baggott, PhD, baggott@ stanford.edu Phase II HLHR13: Testing the Substitution of Brentuximab Vedotin for St. Jude Michael Christina (NCT01920932) Vincristine in the Usual Chemotherapy and Radiation in High-Risk Link Baggott, PhD, Pediatric Hodgkin Lymphoma baggott@ stanford.edu 725 Welch Rd, Palo Alto,
    [Show full text]
  • Subclonal Evolution of Chronic Lymphocytic Leukemia After Allogeneic T Cell Therapies
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2020 Subclonal evolution of chronic lymphocytic leukemia after allogeneic T cell therapies Haven Garber Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Cancer Biology Commons, Immunotherapy Commons, and the Medicine and Health Sciences Commons Recommended Citation Garber, Haven, "Subclonal evolution of chronic lymphocytic leukemia after allogeneic T cell therapies" (2020). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 1044. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1044 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. SUBCLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA AFTER ALLOGENEIC T CELL THERAPIES A DISSERTATION Presented to the Faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY by Haven Rebecca Garber, MD Houston, Texas December 2020 2 Dedication To my children - Scout, Kai, and James.
    [Show full text]
  • Immunogenomic Approaches to More Effective Childhood Cancer Therapies
    Immunogenomic approaches to more effective childhood cancer therapies Kris Bosse, MD Children’s Hospital of Philadelphia (CHOP) University of Pennsylvania Perelman School of Medicine 1 Many Thanks • CHOP/Penn – John Maris – Samantha Buongervino – Maria Lane – Sharon Diskin – Hakon Hakonarson – Kate Krytska – Ben Garcia – Bruce Pawel – Dan Martinez – Dimitri Monos • SBF-Su2C and Moonshot Projects – And many others • UCSC • PPTC Investigators – Crystal Mackall and Kara Davis – David Haussler – Malcolm Smith – Paul Sondel and Ken DeSantes – Sofie Salama • Funding sources for presented – Poul Sorensen and Kirk Schultz – Nikolaos Sgourakis work – Dimiter Dimitrov and Dontcho Jelev – Nabil Ahmed and Will Parsons – NIH, SU2C, St. Baldrick’s, – Mike Jensen and Julie Park • U of Tubingen ALSF, Evan Foundation, – Michael Taylor, Uri Tabor – Stefan Stevanovic Damon Runyon Cancer – and Daniel Morgenstern – Daniel Kowalewski Research Foundation, – Terry Fry and Lia Gore – Moreno Di Marco Zymeworks, Tmunity 2 – Nirali Shah and Rosie Kaplan Poul Sorensen and Patrick Sullivan (Advocate) Michael Jensen Michael Taylor Paul Sondel Terry Fry Dimiter Dimitrov John Maris (Leader) Crystal Mackall (Co-Leader) Rosie Kaplan Nabil Ahmed 3 Immunogenomics to Create New Therapies for High-Risk Childhood Cancers: Expanding the targetable cell surfaceome Class Cluster of Differentiation CD19, CD22, CD99, CD276 CD24,CD33, CD123, CD44v6 Adhesion and Motility Molecules L1CAM, NCAM1 MCAM, ALCAM, CRLF2 Cell Surface Receptors and IL13RA2 SLC6A2, CHRNA5, TEM8 Transporters Gangliosides
    [Show full text]
  • H in November and December of 2014
    SPOTLIGHT ON KIDS HIDE AND SEEK PIONEERING IMMUNOTHERAPY TO FIND AND KILL ELUSIVE CANCER CELLS IN CHILDREN Pediatric cancer specialist Kara Davis was nervous. It was a spring morning in April and she was headed into the hospital to see 11-year- old Salvador De Leon. Sal had leukemia, and he wasn’t doing well. After three grueling years of therapy, his most recent relapse left only one course of action: an experimental treatment to seek out and destroy the cancer cells that had eluded conventional cancer treatments. Davis knew that this approach could either cure him or kill him. The treatment, known as CAR-T cell therapy, relies on the use of a patients’ own genetically modified immune cells to track down and attack the leukemia cells. Although some children with leukemia like Sal’s have experienced stunning, years-long remissions after the therapy, about 30 percent of CAR-T cell recipients experience a temporary but potentially deadly side effect known as cytokine release syndrome. Davis, OD, an assistant professor of pediatrics at the Stanford School of Medicine, was concerned be- cause Sal had reacted poorly to previous rounds of chemotherapy. Did this mean he was likely to struggle with the CAR-T therapy as well? “I was very worried,” Davis recalls. “But there really weren’t any other good options for Sal.” BY KRISTA CONGER PHOTOGRAPHY BY LESLIE WILLIAMSON Salvador De Leon and his mother, Maria De La Cruz 28 FALL 2017 STANFORD MEDICINE When she broached the subject of the new treatment Ronald Levy, MD, a pioneer in the field, concurs.
    [Show full text]
  • March 15, 2018 Broad Institute of MIT and Harvard Cambridge, MA
    March 15, 2018 Broad Institute of MIT and Harvard Cambridge, MA SPONSORED BY: 2018 Organized by: www.bostonsociety.org 2018 AML SPONSORS AGIOS is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company’s website at www.agios.com. IMMUNOGEN is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα- positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen’s ADC technology is also used in Roche’s marketed product, Kadcyla®, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. 1 | PAGE ORGANIZERS’ WELCOME Welcome to the 2018 Acute Myeloid Leukemia Medical Symposium. Our organizers have gathered an excellent group of speakers for the first annual AML symposium. The program is arranged to incorporate extensive audience participation and discussion. We encourage attendees to take full advantage of the opportunity to engage in discussion in order to receive the maximum benefit from the AML experience.
    [Show full text]